News for Co-Diagnostics, Inc. (0A50.L)

Total Revenue: $3.9 million for fiscal year 2024, down from $6.8 million in the prior year.Grant Revenue: $3.1 million in 2024.Product Revenue: $0.8 million in

Mar 27, 2025 / 08:30PM GMTOperator Good day, and welcome to the Co-Diagnostics fourth quarter and full year 2024 earnings conference call. (Operator Instruction

CoDiagnostics (CODX) delivered earnings and revenue surprises of -5.88% and 60.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PR NewswireSALT LAKE CITY, March 27, 2025 SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics compa

Revenue: $3.9 million for the full year 2024, falling short of the annual estimate of $4.14 million.Net Loss: $37.6 million, compared to a net loss of $35.3 mi

PR NewswireSALT LAKE CITY, March 13, 2025 SALT LAKE CITY, March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics compa

PR NewswireSALT LAKE CITY, March 3, 2025 The symposium exploring advances in cancer prevention and care is set to take place on March 4, International HPV

PR NewswireSALT LAKE CITY, Jan. 7, 2025 SALT LAKE CITY, Jan. 7, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a m

Total Revenue: $0.6 million, down from $2.5 million in the prior year same period.Grant Revenue: $0.4 million in the third quarter of 2024.Product Revenue: $0.

Co-Diagnostics, Inc. (NASDAQ:CODX) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsAndrew Benson - Head of Investor...

Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast

Infectious Disease Diagnostics Market size was valued at USD 22.94 billion in 2023 to USD 43.09 billion by 2031...

Total Revenue: $2.7 million, up from $0.2 million in the prior year same period.Grant Revenue: $2.5 million in the second quarter of 2024.Product Revenue: $0.2

Aug 08, 2024 / 08:30PM GMTOperator Good day, and welcome to the Co-Diagnostics second quarter 2024 earnings conference call. (Operator Instructions) Please note

Co-Diagnostics sees shareholder backing in annual meeting votes

Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C.

Co-Diagnostics, Inc. (NASDAQ:NASDAQ:CODX) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ETCompany ParticipantsAndrew Benson - Head, Investor...

According to the latest research report published by DataM Intelligence, the Global Infectious Disease Testing Products Market was valued at US$ 27.8...

/PRNewswire/ -- The point of care molecular diagnostics industry is poised for significant growth and advancements in the near future. With the increasing...